Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor. - Wikidata - awgldk - TriplyDB

Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor.

Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor.

http://www.wikidata.org/entity/Q37675967

about

Intimate cross-talk between cancer cells and the tumor microenvironment of B-cell lymphomas: The key role of exosomes.The Role of Checkpoint Inhibition in Non-Small Cell Lung Cancer.Significant benefit of Nivolumab treating PD-L1 positive metastatic pulmonary carcinosarcoma: a case report and literature review.New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.Ipilimumab for the treatment of metastatic prostate cancer.Immune checkpoint inhibitors in advanced non-small cell lung cancer.Nivolumab Induces Sustained Liver Injury in a Patient with Malignant Melanoma: A Case Report.Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients.The Use of the Humanized Mouse Model in Gene Therapy and Immunotherapy for HIV and Cancer.Optimized Expression and Characterization of a Novel Fully Human Bispecific Single-Chain Diabody Targeting Vascular Endothelial Growth Factor165 and Programmed Death-1 in and Evaluation of Antitumor Activity In Vivo

P2860

Q39376074-60F67060-46FA-4629-A81B-7936F4D3F2E5 Q47095389-F2EA8B95-BA0E-44C6-BDC0-5151B5A5E739 Q47139741-6FC159AA-75D2-4E7D-99C2-7EE0B80256B9 Q47221234-2265DAFD-4958-4E13-A6C4-F4AC7EF9EB20 Q47225399-3C688EF6-A45C-4ADA-8028-07203A486C64 Q47563451-32E999C4-3D83-4E2F-87CE-BDFCA5A6EE4B Q50055764-CBA9D775-B4AA-4DDA-A465-81C15A6B5579 Q52641866-D54532D4-6392-4062-B989-DE466F3BC9AE Q55078034-0EA76ADA-B1E4-45E2-9539-65C31619DB0D Q59138239-8F38BC0A-5027-44E1-A4ED-6640FA37D9EA

P2860

Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor.

http://www.wikidata.org/entity/Q37675967

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 10 February 2017

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor.

@en

Nivolumab as Programmed Death-1

@nl

type

label

Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor.

@en

Nivolumab as Programmed Death-1

@nl

prefLabel

Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor.

@en

Nivolumab as Programmed Death-1

@nl

P1433

Q37675967-A7F05151-8CB9-487C-81F0-8752950057AD

P1476

Q37675967-4AA832C8-A465-4E40-A3FA-384628165EE3

P2093

Q37675967-2C515443-5601-49A6-98F9-C04BD0FEE254

Q37675967-33221BDC-4D90-4D66-8017-3C69665EFCF3

Q37675967-E9A35827-0FA1-451F-AB42-1AD983B1452B

P2860

Q37675967-03B30651-1082-48BF-800E-7609D7FBBFE1

Q37675967-09831051-5430-40FA-BE13-37AF04D1D10E

Q37675967-0EF4DB9A-36FB-4FE7-8F4F-A7E7448C5475

Q37675967-12EB4FAB-8379-4FF6-AA50-8FF4E04CC7DB

Q37675967-1557A067-52AD-49B4-A652-4AAFF6D8738C

Q37675967-19490AB2-3E5C-432D-BBC1-BF051E09E4E9

Q37675967-1A032C72-4B41-4382-B486-35BFFC32856E

Q37675967-1F8947A3-DC57-4EB1-91C2-E32A6822D426

Q37675967-2EF681BA-A09E-4D53-A740-9D5D80C0F4E3

Q37675967-30629277-BC36-40EC-881C-681022785BA5

P304

Q37675967-256CA618-CC70-4DF7-8428-59E90C16D23D

P31

Q37675967-8D6A702C-15B4-4813-8081-F49A39FB1749

P356

Q37675967-3739B323-AE11-46BB-A389-54050940F6C4

P433

Q37675967-66C5CD90-98A6-4346-8618-6CAB68A4CD8B

P478

Q37675967-63FF51B9-443B-4475-8BF2-0D06D9CA9F3D

P577

Q37675967-35C783A8-0BB7-4779-BFB2-70092C2E15EA

P698

Q37675967-64A08C2D-7492-4895-80D3-8D1D8DD429F9

P921

Q37675967-5F19D9A7-8F1A-4D04-BD7B-F3E2E2A62005

P932

Q37675967-949A5935-5688-4174-8064-B4F017206F90

P356

P1433

Journal of Cancer

P1476

Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor.

@en

P2093

Baoan Chen

http://www.w3.org/2001/XMLSchema#string

Haijun Zhang

http://www.w3.org/2001/XMLSchema#string

Liting Guo

http://www.w3.org/2001/XMLSchema#string

P2860

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Clinical utility of nivolumab in the treatment of advanced melanoma

Current Insights into Long Non-Coding RNAs in Renal Cell Carcinoma

Nivolumab in the treatment of malignant melanoma: review of the literature

Nivolumab plus ipilimumab in advanced melanoma.

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

The blockade of immune checkpoints in cancer immunotherapy

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Advances in cancer immunology and cancer immunotherapy

P304

410-416

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.7150/JCA.17144

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2017-02-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28261342

http://www.w3.org/2001/XMLSchema#string

P921

P932

5332892

http://www.w3.org/2001/XMLSchema#string